Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

71.57EUR
7:26am EDT
Change (% chg)

€0.23 (+0.32%)
Prev Close
€71.34
Open
€71.43
Day's High
€71.61
Day's Low
€70.64
Volume
113,456
Avg. Vol
331,701
52-wk High
€75.28
52-wk Low
€54.84

UCB.BR

Chart for UCB.BR

About

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.63
Market Cap(Mil.): €13,876.03
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.13

Financials

  UCB.BR Industry Sector
P/E (TTM): 24.75 29.24 29.98
EPS (TTM): 2.88 -- --
ROI: 7.10 13.55 13.08
ROE: 9.65 14.45 14.23

Ex-UCB executive loses bid to seal whistleblower lawsuit

A federal judge has denied a former UCB SA executive's request to keep a whistleblower lawsuit he filed against the drug company under seal, rejecting his argument that he may face retaliation from his new employer once his identity becomes public.

Mar 08 2017

BRIEF-UCB releases new CIMZIA data in moderate-to-severe plaque psoriasis

* Announced on Saturday that new Cimzia (Certolizumab Pegol) demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis

Mar 06 2017

Pharma group UCB guides for further growth in 2017

BRUSSELS, Feb 23 Belgian pharmaceutical group UCB forecast on Thursday revenues and core profit would continue to grow in 2017 after sales of all of its key drugs were above analysts' expectations in 2016.

Feb 23 2017

BRIEF-UCB FY revenue, operating profit ahead of Reuters poll

* Reports FY revenue of 4.18 billion euros ($4.42 billion) versus 4.12 billion euros in Reuters poll

Feb 23 2017

BRIEF-UCB files Briviact CV in US as monotherapy treatment for adult epilepsy patients with partial-onset seizures

* UCB files Briviact (brivaracetam) CV in the US as monotherapy treatment for adult epilepsy patients with partial-onset seizures Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 19 2017

BRIEF-UCB: CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials

* CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials

Jan 19 2017

BRIEF-UCB says head-to-head study of Cimzia and Humira did not meet primary endpoints

* The Lancet publishes first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in bio-naïve rheumatoid arthritis patients

Nov 15 2016

BRIEF-UCB gives results from phase 3 bridge study

* Results from phase 3 Bridge study showed romosozumab significantly increased bone mineral density in men with osteoporosis

Nov 14 2016

BRIEF-UCB's anti-epileptic drug VIMPAT receives positive opinion by EU CHMP

* UCB's anti-epileptic drug VIMPAT (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures Source text: http://bit.ly/2fIeuV8 Further company coverage: (Gdynia Newsroom)

Nov 11 2016

Belgium's UCB guides for upper end of 2016 forecast range

BRUSSELS, Oct 25 Belgian pharma group UCB on Tuesday said its 2016 results should come in at the upper end of its guidance range, as its main products sold strongly in the first nine months of the year.

Oct 25 2016

More From Around the Web

Earnings vs. Estimates